Clinical Trial

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

Study acronym: TIRO-AF
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-27; most recent amendment 2026-01-12.
Trial Details
NCT Number NCT06802081
Lead Sponsor The Cleveland Clinic
Conditions Atrial Fibrillation, Obesity
Enrollment 100 participants
Start Date 2025-04-08
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-13